AAN: J&J: presents results on nipocalimab

(marketscreener.com) The molecular properties of nipocalimab in the treatment of generalized myasthenia gravis will be presented at the 2024 annual meeting of the American Academy of Neurology.Analysis of clinical and non-clinical studies confirms the potential of the investigational treatment for a rapid, profound and long-lasting decrease in immunoglobulin G says...https://www.marketscreener.com/quote/stock/JOHNSON-JOHNSON-4832/news/J-J-presents-results-on-nipocalimab-46415535/?utm_medium=RSS&utm_content=20240411